Group 1: Company Performance Overview - In the first half of 2025, the company achieved a total outpatient and emergency service volume of 1.3191 million, a year-on-year increase of 5.42% [4] - The company reported operating revenue of CNY 2,034.31 million, a decrease of 15.95% year-on-year, and a net profit attributable to shareholders of CNY -164.96 million, a year-on-year decrease in loss of 4.98% [4] - The operating cash flow net amount was CNY 592.54 million, an increase of 12.75% compared to the same period last year [4] Group 2: Service and Operational Improvements - The company established a senior care center with 100 beds to cater to the needs of elderly patients, including those with Alzheimer's and other disabilities [2] - The company’s hospitals completed 636 clinical application filings for restricted technologies and published 39 SCI papers, enhancing their academic influence [2] - The company improved patient service experience by optimizing the hospitalization settlement and medical insurance reimbursement processes [3] Group 3: Financial Metrics and Cost Management - In Q2 2025, the company achieved operating revenue of CNY 1.037 billion, a quarter-on-quarter increase of 4.02% [4] - The management expense ratio in Q2 was 13.12%, a decrease of 0.95 percentage points from the previous quarter [4] - The company implemented cost control measures, including optimizing personnel costs and enhancing procurement efficiency [6] Group 4: Patient Demographics and Market Reach - The proportion of out-of-town patients at Xi'an Gaoxin Hospital increased to 35%, while at Xi'an International Medical Center Hospital, it rose to 42% from less than 10% [7] - The company is adapting to DRG payment reform, stabilizing inpatient service volume while expanding outpatient services [6] Group 5: Future Outlook and Strategic Initiatives - The company plans to enhance medical quality and service experience while implementing differentiated strategies to build competitive advantages [9] - The proton therapy center, set to open in 2025, will be the first of its kind in Northwest China, significantly improving cancer treatment capabilities in the region [9]

资料显示，西安国际医学投资股份有限公司的主营业务是大健康医疗服务和现代医学技术转化应用。公 司的主要产品是高质量普惠型医疗服务。公司被授予"国家级头痛中心单位""中国幽门螺杆菌分子医学 中心分中心""西北脊柱结核微创诊疗中心"资质认证。公司董事长为史今。 从股票走势来看，国际医学近一年上涨 30.48%。 金融界消息，根据中登公司数据显示，截至上周最后一个交易日（8月22日），国际医学股东质押比例 占总股本22.42%，位居两市第253位。 数据显示，国际医学股东共质押5.02亿股，分为25笔，其中无限售股5.02亿股，质押总市值27.51亿元。 来源：金融界 ...

Group 1 - The core viewpoint of the article indicates that International Medicine (000516) reported a narrowing loss in its 2025 mid-year financial results, with total revenue declining and net profit showing a slight improvement compared to the previous year [1] - The total revenue for the first half of 2025 was 2.034 billion yuan, a decrease of 15.95% year-on-year, while the net profit attributable to shareholders was -165 million yuan, an increase of 4.98% year-on-year [1] - In the second quarter of 2025, the total revenue was 1.037 billion yuan, down 16.86% year-on-year, and the net profit attributable to shareholders was -58.6 million yuan, up 14.68% year-on-year [1] Group 2 - The gross profit margin for the first half of 2025 was 7.8%, a decrease of 17.8% year-on-year, while the net profit margin was -10.73%, down 13.52% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 368 million yuan, accounting for 18.07% of revenue, which is an increase of 15.38% year-on-year [1] - The company reported a cash flow from operating activities of 0.26 yuan per share, an increase of 13.86% year-on-year, while the net asset per share was 1.55 yuan, down 5.13% year-on-year [1] Group 3 - Significant changes in financial items included a 35.37% decrease in income tax expenses due to reduced taxable income, and a 61.98% increase in net cash flow from investing activities due to decreased cash payments for fixed assets and other long-term assets [3] - The net cash flow from financing activities decreased by 54.76% due to reduced cash received from borrowings [3] - Historical data indicates that the company's median return on invested capital (ROIC) over the past decade is -0.2%, with a particularly poor performance in 2022 at -9.75% [3]

据了解，在国家医保局推进住院服务按病种付费后，公司成立DRG核心领导小组，定期召开运营分析 会议，动态优化管理策略，有效提升了医护人员对DRG核心政策的理解深度与执行能力。持续完善 DRG智能监测平台功能，实现了对病例费用的实时监控、入组差异的精准分析，有效预防了不合理医 疗费用的发生。同时，完成了全院医用耗材供应商体系向集中配送模式的切换，实现了耗材从采购到使 用的全流程集约化管控，降低了采购成本。加强医疗器械全生命周期管理，不断提升设备使用效能。此 外，通过领导部署、常态化巡视、夜间巡查以及违规重罚等多措并举，狠抓节能降耗工作，有效降低了 医院整体运营成本。 半年报显示，报告期内新获批科研项目9项。圆满完成了3项国家、省、市级课题的验收工作。发表学术 论文22篇，其中6篇被SCI期刊收录，彰显了学术研究水平；新获得4项专利授权。公司学科实力持续加 强，业务布局更加完善，患者就医体验持续改善，服务边界有序拓展，整体综合实力稳步提升，业界影 响力持续扩大。公司持续拓展医联体合作网络，报告期内新增合作医院13家。截至报告期末，合作医疗 机构总数已达145家，涵盖三级医院18家、二级医院69家、社区卫生院58家， ...

证券代码：000516 证券简称：国际医学 公告编号：2025-039 西安国际医学投资股份有限公司 关于控股股东进行股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 2、世纪新元未来半年内到期的质押股份累计数量118,990,000股， 占其持有本公司股份总数的19.31%，占公司总股本的5.31%，对应融资 金额为2.42亿元；未来一年内到期的质押股份累计数量287,390,000股， 占其持有本公司股份总数的46.65%，占公司总股本的12.84%，对应融资 金额为6.86亿元。 3、本次股份质押风险在可控范围之内，上述股份质押行为不会导 致公司实际控制权的变更。世纪新元资信状况良好，具备较强的资金偿 还能力，还款资金来源包括投资收益、分红、其他收入等，其质押的股 份现不存在平仓风险，且对公司生产经营、公司治理等不产生实质性影 响。后续如出现平仓风险，将采取包括但不限于提前购回、补充质押等 措施应对风险。 | | | | 本次质 | 本次质 | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- ...

Market Overview - The hair medical concept sector declined by 1.01% as of the market close on August 22, ranking among the top decliners in concept sectors [1] - Major stocks in the sector that experienced significant declines include Shuiyang Co., Huabang Health, and Baicheng Pharmaceutical, while stocks that saw gains include Zhendong Pharmaceutical, Kangyuan Pharmaceutical, and International Medicine, with increases of 1.33%, 0.69%, and 0.37% respectively [1] Concept Sector Performance - The top-performing concept sectors today include: - China AI 50: +5.31% - National Big Fund Holdings: +5.00% - SMIC Concept: +3.67% - MCU Chips: +3.64% - Automotive Chips: +3.46% [2] - Conversely, the hair medical sector was among the worst performers, alongside soybean and high-pressure oxygen chamber sectors, which saw declines of 0.94% and 0.76% respectively [2] Capital Flow Analysis - The hair medical concept sector experienced a net outflow of 289 million yuan, with 15 stocks seeing net outflows and 10 stocks exceeding 10 million yuan in outflows [2] - The stock with the highest net outflow was Shuiyang Co., with a net outflow of 123.37 million yuan, followed by Kids King, Jiu Zhi Tang, and Kang En Bei with net outflows of 84.69 million yuan, 48.68 million yuan, and 23.36 million yuan respectively [2] - Stocks with the highest net inflows included Kangyuan Pharmaceutical, Zhendong Pharmaceutical, and Xianju Pharmaceutical, with net inflows of 42.76 million yuan, 31.16 million yuan, and 21.98 million yuan respectively [2][3] Individual Stock Performance - Notable declines in the hair medical sector include: - Shuiyang Co.: -4.82% with a turnover rate of 11.16% and a net outflow of 123.37 million yuan - Kids King: -0.16% with a turnover rate of 4.36% and a net outflow of 84.69 million yuan - Jiu Zhi Tang: -1.92% with a turnover rate of 5.92% and a net outflow of 48.68 million yuan [2] - Stocks with positive performance include: - Zhendong Pharmaceutical: +1.33% with a turnover rate of 6.15% and a net inflow of 31.16 million yuan - Kangyuan Pharmaceutical: +0.69% with a turnover rate of 4.39% and a net inflow of 42.76 million yuan [3]

资金面上看，今日高压氧舱概念板块获主力资金净流出2.60亿元，其中，6股获主力资金净流出，净流 出资金居首的是铁建重工，今日主力资金净流出1.43亿元，净流出资金居前的还有创新医疗、三星医 疗、澳洋健康等，主力资金分别净流出6083.41万元、4365.19万元、1312.28万元。今日主力资金净流入 居前的概念股有国际医学、金陵药业、盈康生命等，主力资金分别净流入335.04万元、327.12万元、 319.53万元。（数据宝） 高压氧舱概念资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 688425 | 铁建重工 | -0.82 | 1.55 | -14260.92 | | 002173 | 创新医疗 | -0.56 | 14.28 | -6083.41 | | 601567 | 三星医疗 | -5.07 | 4.21 | -4365.19 | | 002172 | 澳洋健康 | -1.80 | 6.53 | -1312.28 | | 002430 | 杭氧股份 | 0.97 | ...

2025年8月22日，国际医学(000516.SZ)发布2025年半年度报告。截至2025年8月21日，共有6个机构投资 者披露持有国际医学A股股份，合计持股量达7.42亿股，占国际医学总股本的33.14%。其中，机构投资 者包括陕西世纪新元商业管理有限公司、申华控股集团有限公司、银河德睿资本管理有限公司、西安商 业科技开发公司、申万宏源证券有限公司、香港中央结算有限公司，机构投资者合计持股比例达 33.14%。相较于上一季度，机构持股比例合计下跌了0.46个百分点。 公募基金方面，本期较上一季未再披露的公募基金共计4个，包括汇添富医疗积极成长一年持有混合 A、金鹰策略配置混合、广发资管盛世精选混合A、浙商汇金转型驱动。 外资态度来看，本期较上一季度持股减少的外资基金共计1个，即香港中央结算有限公司，持股减少占 比达0.29%。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 ...

Group 1 - The company will not distribute cash dividends, issue bonus shares, or convert reserves into share capital for the reporting period [2] - The company approved a stock repurchase loan application of RMB 44.5 million from Bank of Communications Shaanxi Branch on April 8, 2025 [7] - The company increased its investment in Xi'an International Medical Center by RMB 380 million, raising its registered capital from RMB 1.4 billion to RMB 1.78 billion [7] Group 2 - The company held its 13th Board of Directors' sixth meeting on August 20, 2025, with all seven directors present [8] - The board approved the 2025 semi-annual report and its summary with unanimous consent [9] - The board proposed amendments to the company's articles of association and various governance rules, which require shareholder approval [10][12] Group 3 - The company announced the resignation of several board members due to governance structure adjustments following the revision of the Company Law [26] - The resigning members will continue to hold other positions within the company [27] - The company expressed gratitude for the contributions of the departing members during their tenure [28] Group 4 - The company will hold its first extraordinary general meeting of 2025 on September 8, 2025, at 2:45 PM [30][31] - Shareholders can participate in the meeting through both on-site voting and online voting [33] - The deadline for shareholder registration is September 3, 2025 [34]

国际医学股价报5.46元，与前一交易日收盘价持平。开盘价为5.46元，最高触及5.52元，最低下探5.43 元，成交量为34.55万手，成交金额1.89亿元。 8月21日主力资金净流出272.54万元，近五日主力资金累计净流出2951.15万元。 风险提示：投资有风险，决策需谨慎。 来源：金融界 国际医学属于医疗服务行业，公司以大健康医疗服务和现代医学技术转化应用为主业。主要运营西安高 新医院和西安国际医学中心医院，通过医养结合模式提供多样化医疗健康服务。 公司披露2025年半年度报告显示，上半年实现营业收入20.34亿元，同比下降15.95%；归母净利润亏损 1.65亿元，较上年同期亏损1.74亿元有所收窄。经营活动产生的现金流量净额为5.93亿元，同比增长 12.75%。此外，公司部分董事、监事因《公司法》修订带来的治理架构调整原因辞去相关职务。 ...